Physician
Hematology
Dr. Francisco H. Dexeus, MD
|
|
Give Review
Francisco Dexeus is an expert in the field of Hematology. Francisco Dexeus is a published MD as well. He has 41 publications published. The latest was: Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer. Francisco H. Dexeus, MD is registered with Medicare.
Publications
- Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer.
- Complete responses in metastatic transitional cell carcinoma of the prostate with cisplatin regimens.
- Phase II study of spirogermanium in metastatic prostate cancer.
- Cyclophosphamide and sequential cisplatin for advanced seminoma: long-term followup in 52 patients.
- Adjuvant chemotherapy of bladder cancer: a preliminary report.
- Clinical and radiologic staging of locally advanced and inoperable bladder carcinoma.
- Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update.
- Cyclophosphamide, doxorubicin and cisplatin chemotherapy for patients with locally advanced urothelial tumors with or without nodal metastases.
- Clinical and radiological correlation of retroperitoneal metastasis from nonseminomatous testicular cancer treated with chemotherapy.
- Radiation therapy-associated invasive bladder tumors.
- Cisplatin, cyclophosphamide and doxorubicin chemotherapy for unresectable urothelial tumors: the M.D. Anderson experience.
- Genetic abnormalities in men with germ cell tumors.
- Interferon alternating with chemotherapy for patients with metastatic renal cell carcinoma.
- Chemotherapy of extragonadal germ cell tumors.
- CT and MR imaging of malignant germ cell tumor of the undescended testis.
- Pulmonary air cyst associated with combination chemotherapy containing bleomycin.
- Primary chemotherapy for clinical stage II nonseminomatous germ cell tumors of the testis: a follow-up of 50 patients.
- Cyclic chemotherapy with cyclophosphamide, doxorubicin, and cisplatin plus vinblastine and bleomycin in advanced germinal tumors. Results with 100 patients.
- Carcinoembryonic antigen and beta-human chorionic gonadotropin as serum markers for advanced urothelial malignancies.
- Relationship of thyroid disease to renal cell carcinoma. An epidemiologic study.
- The impact of chemotherapy on the survival of patients with metastatic urothelial tumors.
- A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.
- Escalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony-...
- Chemotherapy immediately after surgery for patients with germ cell tumors.
- Phase II study of coumarin and cimetidine in patients with metastatic renal cell carcinoma.
- Cisplatin combination chemotherapy for elderly patients with urothelial tumours.
- Perianal ulcer in disseminated histoplasmosis.
- Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases.
- Fluorouracil and recombinant human interferon alfa-2a in the treatment of metastatic chemotherapy-refractory urothelial tumors.
- Association of germ cell tumors and Hodgkin's disease.
- Circadian infusion of floxuridine in patients with metastatic renal cell carcinoma.
- Combination chemotherapy with methotrexate, bleomycin and cisplatin for advanced squamous cell carcinoma of the male genital tract.
- Serum biomarkers in metastatic renal cell carcinoma.
- Intensive chemotherapy for metastatic nonseminomatous germ cell tumors.
- Evidence of malignant features in histologically mature teratoma.
- Testicular germ cell tumors. Clinically relevant pathologic findings.
- Phase II study of interferon-alpha and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer.
- Acute thyroid dysfunction (thyroiditis) after therapy with interleukin-2.
- Hyperthyroidism in men with germ cell tumors and high levels of beta-human chorionic gonadotropin.
- Chemotherapy for small cell carcinoma of prostatic origin.
Procedures Preformed
- Hematologic Disorder Treatment
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Education
-
Autonomous University of Barcelona Faculty of Medicine
Drug Facts
| NPI NUMBER | 1578589305 | |
| NPPES Provider LastName | DEXEUS | |
| NPPES Provider FirstName | FRANCISCO | |
| NPPES Provider ZIPCode | 737015928 | |
| NPPES Provider State | OK | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 3854.0 | |
| Distinct Opioid Count | 11.0 | |
| Opioid Claim Count | 511.0 | |
| Percent Opioid Claims | 13.26 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1578589305 |
| Last Name Of The Provider | DEXEUS |
| First Name Of The Provider | FRANCISCO |
| View All |
Similar Doctors
|
|
Dr. Abby R. Bova, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Craig L. Reitz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jess F. Armor, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Akinola O. Ogundipe, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James E. Reeves Jr., MD |
|
|
Dr. Christopher L. Thompson, MD |